Semaglutide vs tirzepatide — which GLP-1 peptide has better research outcomes?

This is the comparison everyone asks about, so let's break it down properly with what the published research actually shows.

Semaglutide (GLP-1 agonist only)
Semaglutide activates the GLP-1 receptor, which slows gastric emptying, reduces appetite, and improves insulin sensitivity. The STEP trial program showed average weight reduction of approximately 15% of body weight over 68 weeks at the 2.4mg dose. It's the most studied GLP-1 peptide and has the longest track record in research.

Side effects are primarily GI — nausea, especially during dose titration. Most researchers report this subsides after 4-6 weeks at a stable dose. The standard titration protocol starts at 0.25mg weekly and increases every 4 weeks.

Tirzepatide (dual GLP-1 + GIP agonist)
Tirzepatide is a dual agonist — it activates both GLP-1 and GIP receptors. The SURMOUNT-1 trial showed average weight reduction of approximately 21% at the highest dose over 72 weeks. That's a meaningful difference compared to semaglutide.

The dual mechanism appears to provide better glycemic control and potentially better preservation of lean mass, though the lean mass data is still being studied. Side effects are similar to semaglutide but some researchers report slightly less nausea.

The practical considerations:
Tirzepatide shows better numbers in trials, but semaglutide has a much longer research history and more real-world data. Semaglutide is also more widely available and has more vendor options in the research peptide space.

Dosing is different between the two — they are NOT interchangeable on a mg-for-mg basis. Tirzepatide starts at 2.5mg weekly vs semaglutide at 0.25mg. Do not convert between them without understanding the different potency profiles.

What to consider for your research:
If you're new to GLP-1 research, semaglutide has more literature, more community data, and a more straightforward titration. If you've researched semaglutide already and want to explore dual agonism, tirzepatide is the logical next step.

Both require proper reconstitution, cold storage, and precise dosing. Neither is a magic bullet — they work best alongside structured nutrition and activity protocols.

What has your experience been with either? Drop your observations below.